Is Vor Biopharma Inc. Trading At A 49 percent Discount?
| VOR Stock | USD 1.27 0.43 51.19% |
Slightly above 55% of Vor Biopharma's retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Vor Biopharma suggests that some traders are interested. Vor Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in Vor Biopharma. Many technical investors use Vor Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Vor |
Key Insights Vor Biopharmas estimated fair value is US9.25 based on 2 Stage Free Cash Flow to Equity Vor Biopharmas...
Read at simplywall.st
 |
Vor Biopharma Fundamental Analysis
We analyze Vor Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vor Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vor Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Vor Biopharma is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Vor Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vor Biopharma stock to make a market-neutral strategy. Peer analysis of Vor Biopharma could also be used in its relative valuation, which is a method of valuing Vor Biopharma by comparing valuation metrics with similar companies.
Peers
Vor Biopharma Related Equities
| STTK | Shattuck Labs | 11.71 | ||||
| LYRA | Lyra Therapeutics | 5.56 | ||||
| VTYX | Ventyx Biosciences | 2.15 | ||||
| BOLT | Bolt Biotherapeutics | 1.96 | ||||
| ERAS | Erasca | 1.95 | ||||
| ACLX | Arcellx | 1.86 | ||||
| AUTL | Autolus Therapeutics | 0.44 | ||||
| KNSA | Kiniksa Pharmaceuticals | 0.35 | ||||
| DAWN | Day One | 0.23 | ||||
| NUVL | Nuvalent | 2.14 | ||||
| GLUE | Monte Rosa | 2.22 | ||||
| EWTX | Edgewise Therapeutics | 3.10 | ||||
| ACET | Adicet Bio | 3.58 | ||||
| DSGN | Design Therapeutics | 3.70 | ||||
| NRIX | Nurix Therapeutics | 4.11 | ||||
| KYMR | Kymera Therapeutics | 4.55 | ||||
| FHTX | Foghorn Therapeutics | 5.30 | ||||
| CGEM | Cullinan Oncology | 6.82 |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.